![Noxxon Pharma NV](/common/images/company/EU_ALTME.png)
NOX-E36 bietet vielversprechende Entwicklungsmöglichkeiten für Augenkrankheiten mit einem hohen Bedarf an gut verträglichen Therapien mit antifibrotischer Wirkung Die antifibrotische...
NOX-E36 presents promising opportunity for development in eye diseases with a high need for well-tolerated therapies with anti-fibrotic effect Anti-fibrotic mode of action of NOX-E36 was...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.0146 | 10.2816901408 | 0.142 | 0.1644 | 0.142 | 511726 | 0.15351143 | DE |
4 | -0.0044 | -2.73291925466 | 0.161 | 0.1648 | 0.1272 | 405959 | 0.14845987 | DE |
12 | -0.0859 | -35.4226804124 | 0.2425 | 0.26 | 0.1272 | 322743 | 0.18075154 | DE |
26 | -0.0564 | -26.4788732394 | 0.213 | 0.436 | 0.1272 | 848648 | 0.27384097 | DE |
52 | -1.2394 | -88.782234957 | 1.396 | 1.9 | 0.1272 | 519626 | 0.32136483 | DE |
156 | 0.1148 | 274.641148325 | 0.0418 | 5.98 | 0.0398 | 301480 | 0.40045678 | DE |
260 | 0.1148 | 274.641148325 | 0.0418 | 5.98 | 0.0398 | 301480 | 0.40045678 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.